In accordance with our findings, Barry-Hamilton et al. [7] demonstrated efficacy of an LOXL2-targeting antibody in reduction of bone and soft tissue metastases after intracardiac injection of human breast cancer cells [7]. The gene discussed is LOXL2; the disease is breast carcinoma.